Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?

Chepy, Aurélien; Bourel, Louisa; Koether, Vincent; Launay, David; Dubucquoi, Sylvain; Sobanski, Vincent

Chepy, Aurélien; Bourel, Louisa; Koether, Vincent; Launay, David; Dubucquoi, Sylvain; Sobanski, Vincent.

Afiliação

Chepy A; Univ. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.
Bourel L; CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France.
Koether V; Univ. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.
Launay D; Univ. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.
Dubucquoi S; CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France.
Sobanski V; Univ. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.

Front Immunol ; 13: 930970, 2022.

Article em En | MEDLINE | ID: mdl-35837382

Assuntos

Anticorpos Antinucleares; Escleroderma Sistêmico; Autoanticorpos; Fibrose; Humanos; Escleroderma Sistêmico/diagnóstico

Palavras-chave

antibodies; antinuclear antibodies (ANA); biomarkers; pathogenic antibody; systemic sclerosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Anticorpos Antinucleares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google